Fulcrum Therapeutics Inc (NASDAQ: FULC) kicked off on Monday, down -6.04% from the previous trading day, before settling in for the closing price of $7.45. Over the past 52 weeks, FULC has traded in a range of $2.92-$13.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -1.10%. While this was happening, its average annual earnings per share was recorded -2.52%. With a float of $57.79 million, this company’s outstanding shares have now reached $61.92 million.
The extent of productivity of a business whose workforce counts for 76 workers is very important to gauge.
Fulcrum Therapeutics Inc (FULC) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Fulcrum Therapeutics Inc is 7.03%, while institutional ownership is 91.70%. The most recent insider transaction that took place on May 07 ’24, was worth 1,831. In this transaction Principal Accounting Officer of this company sold 236 shares at a rate of $7.76, taking the stock ownership to the 11,571 shares. Before that another transaction happened on Mar 08 ’24, when Company’s Vice President, Finance sold 4,884 for $11.72, making the entire transaction worth $57,219. This insider now owns 11,807 shares in total.
Fulcrum Therapeutics Inc (FULC) Latest Financial update
In the latest quarterly report, which was put into the public domain on 3/31/2024, the organization reported -0.38 earnings per share (EPS), higher than consensus estimate (set at -0.44) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -2.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.40% during the next five years compared to 1.09% growth over the previous five years of trading.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Trading Performance Indicators
Take a look at Fulcrum Therapeutics Inc’s (FULC) current performance indicators. Last quarter, stock had a quick ratio of 20.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 173.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.61, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.61 in one year’s time.
Technical Analysis of Fulcrum Therapeutics Inc (FULC)
The latest stats from [Fulcrum Therapeutics Inc, FULC] show that its last 5-days average volume of 0.74 million was superior to 0.61 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 15.37%. Additionally, its Average True Range was 0.49.
During the past 100 days, Fulcrum Therapeutics Inc’s (FULC) raw stochastic average was set at 4.69%, which indicates a significant decrease from 5.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.12% in the past 14 days, which was higher than the 61.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.63, while its 200-day Moving Average is $6.76. Now, the first resistance to watch is $7.35. This is followed by the second major resistance level at $7.70. The third major resistance level sits at $7.92. If the price goes on to break the first support level at $6.78, it is likely to go to the next support level at $6.56. The third support level lies at $6.21 if the price breaches the second support level.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Key Stats
The company with the Market Capitalisation of 435.05 million has total of 62,154K Shares Outstanding. Its annual sales at the moment are 2,810 K in contrast with the sum of -97,340 K annual income. Company’s last quarter sales were recorded 870 K and last quarter income was -24,760 K.
